Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Loteprednol Etabonate Gel in Healthy Volunteers
NCT03063489Phase 1Completed
- Sponsor
- Valeant Pharmaceuticals
- Start
- Feb 2015
- Primary completion
- May 2015
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of loteprednol etabonate ophthalmic gel 0.38% in ocular inflammation, sponsored by Valeant Pharmaceuticals. Primary endpoint: Loteprednol etabonate concentrations in plasma at 2 weeks. Started Feb 2015; status: completed.
02
Drugs
loteprednol etabonate ophthalmic gel 0.38%
03
Conditions
ocular inflammation
Beyond the preview
Go deeper on NCT03063489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03063489.